Kazi Khan, MD
Nephrology · Salisbury, MDNPI 1063402857
Payments from drug & device makers
Across 364 payments — averaging $21.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$1K
- AstraZeneca$999
- Bayer$768
- Amgen$657
- Akebia Therapeutics Inc$631
- OPKO Pharmaceuticals, LLC$422
- plus $3K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 36 | $1,151 |
| AstraZeneca(2 entities) | 46 | $999 |
| Bayer | 35 | $768 |
| Amgen | 24 | $657 |
| Akebia Therapeutics Inc | 38 | $631 |
| OPKO Pharmaceuticals, LLC | 23 | $422 |
| Vifor Pharma, Inc. | 22 | $406 |
| Otsuka America Pharmaceutical, Inc. | 18 | $347 |
| Novartis | 17 | $345 |
| Calliditas Therapeutics US Inc. | 17 | $329 |
| ANI Pharmaceuticals, Inc. | 14 | $321 |
| Fresenius USA Marketing, Inc. | 12 | $249 |
| Aurinia Pharma U.S., Inc. | 8 | $210 |
| Travere Therapeutics, Inc. | 13 | $201 |
| Boehringer Ingelheim | 6 | $174 |
| GSK | 10 | $173 |
| Ardelyx, Inc. | 6 | $159 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $97 |
| Alnylam Pharmaceuticals Inc. | 2 | $54 |
| Mallinckrodt Enterprises LLC | 2 | $51 |
| Lilly USA, LLC | 2 | $47 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $45 |
| Cycle Pharmaceuticals Inc | 1 | $21 |
| Cormedix Inc. | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Apellis Pharmaceuticals, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Novo Nordisk | 1 | $15 |
| Baxter Healthcare | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
How this compares
$8,000 in reported general payments places this provider in the 85th percentile of 285 nephrology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Salisbury
- Karen DahSalisbury$9K
- Christopher SperatiBaltimore$1.5M
- Michelle EstrellaBaltimore$1.2M
- Mohamed AttaBaltimore$1.1M
- Chirag ParikhBaltimore$1M
- Mario BelledonnePotomac$715K
- Matthew WeirBaltimore$518K
- Kiran SamindlaFrederick$491K
- Saeed KronfliTakoma Park$463K
- Duvuru GeethaBaltimore$409K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.